Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Aclaris Therapeutics (ACRS) Gross Margin (2017 - 2025)

Aclaris Therapeutics (ACRS) has 9 years of Gross Margin data on record, last reported at 58.92% in Q4 2025.

  • For Q4 2025, Gross Margin fell 3343.0% year-over-year to 58.92%; the TTM value through Dec 2025 reached 73.28%, down 1180.0%, while the annual FY2025 figure was 73.28%, 1180.0% down from the prior year.
  • Gross Margin reached 58.92% in Q4 2025 per ACRS's latest filing, down from 83.69% in the prior quarter.
  • Across five years, Gross Margin topped out at 95.87% in Q4 2023 and bottomed at 20.51% in Q1 2022.
  • Average Gross Margin over 5 years is 62.68%, with a median of 67.15% recorded in 2024.
  • Peak YoY movement for Gross Margin: soared 6524bps in 2022, then tumbled -3343bps in 2025.
  • A 5-year view of Gross Margin shows it stood at 23.45% in 2021, then soared by 278bps to 88.69% in 2022, then increased by 8bps to 95.87% in 2023, then decreased by -4bps to 92.35% in 2024, then tumbled by -36bps to 58.92% in 2025.
  • Per Business Quant database, its latest 3 readings for Gross Margin were 58.92% in Q4 2025, 83.69% in Q3 2025, and 71.02% in Q2 2025.